David Hyman, MD, Memorial Sloan-Kettering Cancer Center, presenting Abstract LBA2501, The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers, during Developmental Therap
Du skal være logget ind for at skrive en kommentar.
Forside » Forskning » Nyt lægemiddel virker mod mange kræfttyper » David Hyman, MD, Memorial Sloan-Kettering Cancer Center, presenting Abstract LBA2501, The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers, during Developmental Therap
